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BACKGROUND
This open-label, randomized, phase 3 study compared melphalan at a dose of 
200 mg per square meter of body-surface area plus autologous stem-cell transplan-
tation with melphalan–prednisone–lenalidomide (MPR) and compared lenalidomide 
maintenance therapy with no maintenance therapy in patients with newly diag-
nosed multiple myeloma.
METHODS
We randomly assigned 273 patients 65 years of age or younger to high-dose mel-
phalan plus stem-cell transplantation or MPR consolidation therapy after induction, 
and 251 patients to lenalidomide maintenance therapy or no maintenance therapy. 
The primary end point was progression-free survival.
RESULTS
The median follow-up period was 51.2 months. Both progression-free and overall 
survival were significantly longer with high-dose melphalan plus stem-cell trans-
plantation than with MPR (median progression-free survival, 43.0 months vs. 22.4 
months; hazard ratio for progression or death, 0.44; 95% confidence interval [CI], 
0.32 to 0.61; P<0.001; and 4-year overall survival, 81.6% vs. 65.3%; hazard ratio for 
death, 0.55; 95% CI, 0.32 to 0.93; P = 0.02). Median progression-free survival was sig-
nificantly longer with lenalidomide maintenance than with no maintenance (41.9 
months vs. 21.6 months; hazard ratio for progression or death, 0.47; 95% CI, 0.33 to 
0.65; P<0.001), but 3-year overall survival was not significantly prolonged (88.0% 
vs. 79.2%; hazard ratio for death, 0.64; 95% CI, 0.36 to 1.15; P = 0.14). Grade 3 or 4 
neutropenia was significantly more frequent with high-dose melphalan than with 
MPR (94.3% vs. 51.5%), as were gastrointestinal adverse events (18.4% vs. 0%) and 
infections (16.3% vs. 0.8%); neutropenia and dermatologic toxic effects were more 
frequent with lenalidomide maintenance than with no maintenance (23.3% vs. 0% 
and 4.3% vs. 0%, respectively).
CONCLUSIONS
Consolidation therapy with high-dose melphalan plus stem-cell transplantation, as 
compared with MPR, significantly prolonged progression-free and overall survival 
among patients with multiple myeloma who were 65 years of age or younger. Le-
nalidomide maintenance, as compared with no maintenance, significantly prolonged 
progression-free survival. (Funded by Celgene; ClinicalTrials.gov number, NCT00551928.)
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High-dose chemotherapy plus au-tologous stem-cell transplantation, as compared with conventional chemother-
apy, prolongs progression-free survival and over-
all survival among patients with newly diag-
nosed multiple myeloma.1-4 and it is currently the 
standard of care for patients who are younger 
than 65 years of age. However, since autologous 
stem-cell transplantation has substantial toxic 
effects and requires prolonged hospitalization, 
the comparison with less toxic, orally adminis-
tered treatments is important. Immunomodula-
tory drugs and proteasome inhibitors have sig-
nificantly improved outcomes in patients, regardless 
of whether they are eligible for transplantation.5-18 
These improvements have raised questions about 
the role of transplantation in comparison with 
conventional chemotherapy and about the tim-
ing of transplantation, since the survival benefit 
has not been clearly established.
Continuous treatment with immunomodula-
tory drugs and proteasome inhibitors has shown 
clinical efficacy.19 In three large, randomized stud-
ies, continuous therapy with lenalidomide, as com-
pared with placebo, significantly reduced the risk 
of disease progression (hazard ratio, 0.34 to 0.50), 
but the survival advantage was inconsistent.16-18 
It is currently not clear whether maintenance 
therapy after combination therapy will have the 
same effect that it does after transplantation. To 
address these issues, we conducted a phase 3 study 
to assess the efficacy and safety of melphalan at 
a dose of 200 mg per square meter of body-sur-
face area (high-dose melphalan) plus stem-cell 
transplantation as compared with melphalan–
prednisone–lenalidomide (MPR), followed by le-
nalidomide as maintenance therapy as compared 
with no maintenance therapy, in patients with 
newly diagnosed multiple myeloma who were eli-
gible for transplantation.
Me thods
Patients
Patients with symptomatic, measurable, newly di-
agnosed multiple myeloma who were 65 years of 
age or younger were eligible for this trial. Other 
inclusion criteria were a Karnofsky performance-
status score of at least 60% (on a scale from 0 to 
100%, with lower scores indicating greater dis-
ability) and life expectancy longer than 6 months, 
an absolute neutrophil count greater than 1500 
per cubic millimeter3 and a platelet count great-
er than 75,000 per cubic millimeter,3 and normal 
cardiac and pulmonary-function findings and 
adequate renal function (creatinine clearance 
≥30 ml per minute). The main exclusion criteria 
included a history of other cancers within the 
past 3 years and peripheral neuropathy of grade 
2 or higher. The study was approved by the insti-
tutional review boards of the participating centers 
and was conducted according to the Declaration of 
Helsinki and the International Conference on 
Harmonisation Guidelines for Good Clinical 
Practice. All patients provided written informed 
consent.
Study Design and Oversight
The study was a randomized, open-label trial with 
a 2-by-2 factorial design. We recruited patients 
from November 2007 through July 2009 at 62 cen-
ters in Italy and Israel. A simple randomization 
sequence, stratified according to International 
Staging System disease stage20 (stage I or II vs. 
stage III, with higher stages indicating more se-
vere disease) and age (≤60 years vs. 61 to 65 years), 
was generated by a computer program and im-
plemented by means of a Web-based procedure. 
All patients were randomly assigned (in a 1:1:1:1 
ratio) at enrollment to one of the four groups, but 
the results of the random assignment were con-
cealed until patients reached the end of the induc-
tion period and their eligibility for the consolida-
tion and maintenance regimens was confirmed.
The study was designed by the senior academic 
authors. The sponsor, Fondazione Neoplasie 
Sangue Onlus, collected the data and, in collabo-
ration with the senior academic authors, conducted 
the data analyses. Celgene provided an unrestricted 
grant to conduct the trial but was not involved in 
the data collection, analysis, or the writing of the 
manuscript. The first draft of the manuscript was 
developed by the first author; subsequent drafts 
were revised by the first three authors. A medical 
writer paid by Celgene provided assistance with 
the writing of the manuscript to improve clarity 
and consistency. All authors had full access to the 
primary data and results of the final analysis, 
were responsible for the content of the manuscript 
and the decision to submit it for publication, and 
vouch for the accuracy and completeness of the 
data and the fidelity of the study to the protocol. 
The protocol and statistical analysis plan are avail-
able with the full text of this article at NEJM.org.
The New England Journal of Medicine 
Downloaded from nejm.org at IRCCS Studio e la Cura dei Tumori - Milano on September 5, 2014. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
n engl j med 371;10 nejm.org September 4, 2014 897
Tr ansplantation and Maintenance in Multiple Myeloma
Study Treatments
All patients received induction therapy consist-
ing of four 28-day cycles of lenalidomide (at a 
dose of 25 mg daily on days 1 through 21) plus 
dexamethasone (40 mg daily on days 1, 8, 15, 
and 22). Cyclophosphamide and granulocyte col-
ony-stimulating factor were used to mobilize 
stem cells.21 The consolidation regimen consist-
ed of six 28-day cycles of melphalan (at a dose of 
0.18 mg per kilogram of body weight on days 1 
through 4), prednisone (2 mg per kilogram on 
days 1 through 4), and lenalidomide (10 mg on 
days 1 through 21), or two 4-month cycles of 
melphalan at a dose of 200 mg per square meter 
of body-surface area followed by autologous stem-
cell transplantation. Patients in whom progres-
sive disease developed during induction or consoli-
dation therapy were treated according to local 
standards and remained in the trial for later out-
come evaluations. Maintenance therapy was ini-
tiated within the first 3 months after completion 
of consolidation therapy. Maintenance therapy 
with lenalidomide (10 mg on days 1 through 21 
of each 28-day cycle) was administered until dis-
ease progression or the development of unaccept-
able adverse effects. Details of dose reductions, 
drug discontinuations, and treatment schedules 
are provided in Table S1 in the Supplementary 
Appendix, available at NEJM.org. Details of the 
anticoagulation regimen used have been published 
previously.22
End Points and Assessments
The primary study end point was progression-
free survival. Secondary end points included over-
all survival, the overall response rate, the time to 
a response, and safety. Time-to-event end points 
were estimated from the time of enrollment (for 
all patients) and from the time when the random 
assignment was disclosed (for the patients who 
underwent randomization). Progression-free sur-
vival was calculated until the date of disease 
progression, death from any cause during treat-
ment, or data censoring at the last date on which 
the patient was known to be free of disease pro-
gression. Overall survival was calculated until 
the date of either death from any cause or data 
censoring at the last date on which the patient 
was known to be alive. Response was assessed 
with the use of the International Uniform Response 
Criteria for Multiple Myeloma.23 Bone marrow 
samples were collected at enrollment and analyzed 
by central laboratories within each country. These 
samples were tested for chromosome deletions 
13 and 17 and for the t(4:14) and t(14:16) trans-
locations with the use of fluorescence in situ hy-
bridization. No prospective decisions regarding 
therapy were based on the results. Adverse events 
were graded according to the National Cancer 
Institute Common Terminology Criteria for Ad-
verse Events (version 3.0).24
Statistical Analysis
The primary comparison was between high-dose 
melphalan with stem-cell transplantation and 
MPR. With a two-sided alpha error of 0.05, we 
estimated that 400 patients (200 per treatment 
group) would need to be enrolled for the study 
to have a statistical power of 85% to detect a haz-
ard ratio of 0.62 in favor of high-dose melphalan 
versus MPR (corresponding to a 2-year progression-
free survival of 65% vs. 50%), assuming 2 years 
of accrual, a minimum follow-up time of 1 year, 
and a dropout rate of 5%. The secondary compari-
son was between lenalidomide maintenance ther-
apy and no maintenance therapy. We expected 
that approximately 240 patients (120 per treat-
ment group) would be eligible for a maintenance 
regimen after consolidation treatment. With a 
two-sided alpha error of 0.05, this sample size 
had a statistical power of 80% to detect an im-
provement from 60% to 75% in 2-year progres-
sion-free survival in favor of the maintenance 
group (corresponding to a hazard ratio of 0.56).
To estimate the effect of the complete treat-
ment strategy (induction, consolidation, and main-
tenance phases), both progression-free survival 
and overall survival were estimated for the four 
groups from the date of study enrollment, in an 
analysis that included all enrolled patients. All 
comparative analyses were performed with an 
intention-to-treat approach for the two random-
ized populations: the consolidation-phase popu-
lation, which comprised all patients who were 
eligible to receive high-dose melphalan or MPR 
(the starting time of the analyses was the date of 
disclosure of randomization), and the mainte-
nance-phase population, which comprised all 
patients who were eligible to receive lenalido-
mide maintenance therapy or no maintenance 
therapy (the starting time of the analyses was 
the date of clinical evaluation after the consoli-
dation phase). Two interim analyses, according 
to the O’Brien–Fleming design, were specified 
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57 Were assigned to no
maintenance after MPR
consolidation
59 Were assigned to lenalidomide
maintenance after MPR
consolidation
67 Were assigned to lenalidomide
maintenance after high-dose
melphalan consolidation
399 Entered induction–mobilization phase
273 Were eligible and underwent randomization to
consolidation with high-dose melphalan plus 
autologous stem-cell transplantation or MPR
251 Were eligible and underwent randomization
to maintenance or no maintenance
402 Patients were enrolled
3 Were not eligible
2 Did not meet screening criteria
1 Withdrew consent
126 Discontinued during induction–
mobilization phase
8 Died
16 Had toxic effects
1 Was lost to follow-up
20 Had protocol violation
46 Had disease progression
13 Withdrew consent
21 Chose other medical treatment
1 Was nonadherent
141 Were assigned to and received
high-dose melphalan plus 
stem-cell transplantation
132 Were assigned to and received MPR
6 Discontinued consolidation
therapy
1 Had protocol violation
5 Had disease progression
16 Discontinued consolidation
therapy
1 Died
4 Had toxic effects
1 Was lost to follow-up
10 Had disease progression
1 Discontinued owing
to withdrawal of
consent
59 Entered maintenance phase
44 Discontinued during
maintenance phase
1 Was lost to follow-up
39 Had disease progression
2 Withdrew consent
2 Chose other medical
treatment
56 Entered no-maintenance phase
51 Discontinued during
no-maintenance phase
1 Was lost to follow-up
50 Had disease progression
59 Entered no-maintenance phase
40 Discontinued during 
no-maintenance phase
2 Died
1 Was lost to follow-up
37 Had disease progression
57 Entered maintenance phase
27 Discontinued during
maintenance phase
6 Had toxic effects
14 Had disease progression
4 Withdrew consent
2 Chose other medical
treatment
1 Did not adhere to
maintenance regimen
10 Discontinued
4 Chose other medical
treatment
1 Had protocol
violation
4 Withdrew consent
1 Did not adhere to
   maintenance regimen
9 Discontinued
1 Had toxic effects
1 Was lost to
follow-up
3 Had disease
progression
4 Withdrew consent
68 Were assigned to no
maintenance after high-dose
melphalan consolidation
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by the protocol for the comparison of high-dose 
melphalan with MPR: the first when 65 progres-
sion events (40% of the expected number) had 
occurred, and the second when 97 events (60% of 
the expected number) had occurred; the study 
was completed as originally planned.
The safety-analysis population included all 
patients who received at least one dose of the study 
treatments. Response and safety data were com-
pared among the treatment groups by means of 
the chi-square test or Fisher’s exact test, as appro-
priate. Time-to-event data were analyzed with the 
use of the Kaplan–Meier method, and the groups 
were compared with the use of the log-rank test. 
Cox proportional-hazards models were used to 
estimate hazard ratios and 95% confidence inter-
vals for the main comparisons. Cox models, ad-
justed for age and International Staging System 
stage, were also used to explore any modification 
of the effect of consolidation or maintenance 
therapy between subgroups (including the sub-
groups that were prespecified according to age 
and disease stage), with the use of interaction 
terms. Between-group differences in patient char-
acteristics were evaluated with the use of the 
Mann–Whitney U test for continuous variables 
and the chi-square test or Fisher’s exact test for 
categorical variables, as appropriate. Statistical 
analyses were performed with the use of SAS soft-
ware, version 8.2 (SAS Institute), and Stata 
software, version 11.0 (StataCorp). The data 
cutoff point was April 30, 2013.
R esult s
Patients
A total of 402 patients were enrolled; 399 entered 
the common induction and mobilization phase, 
and 273 remained eligible for random assignment 
to consolidation therapy with high-dose melpha-
lan or MPR. At the end of consolidation therapy, 
251 patients were also eligible for the random-
ized comparison between maintenance therapy 
and no maintenance therapy (Fig. 1). Baseline de-
mographic and disease characteristics were well 
balanced among the treatment groups (Table S2 
in the Supplementary Appendix). At the data cut-
off point, 237 patients had disease progression or 
had died, 45 patients (23%) were still receiving 
lenalidomide maintenance therapy, and 24 patients 
(11%) were not receiving maintenance therapy. 
The median duration of follow-up from the time 
of enrollment was 51.2 months (range, 1 to 66).
Efficacy
In the total enrolled population (402 patients), 
the median progression-free survival from the time 
of diagnosis was 54.7 months among patients 
who received high-dose melphalan plus lenalido-
mide maintenance therapy, 37.4 months among 
patients who received high-dose melphalan with-
out maintenance therapy, 34.2 months among 
patients who received MPR plus lenalidomide 
maintenance therapy, and 21.8 months among 
patients who received MPR without maintenance 
therapy (Fig. 2A). The 5-year overall survival rate 
was 78.4% among patients who received high-
dose melphalan plus lenalidomide maintenance 
therapy, 66.6% among patients who received high-
dose melphalan without maintenance therapy, 
70.2% among patients who received MPR plus 
lenalidomide maintenance therapy, and 58.7% 
among patients who received MPR without main-
tenance therapy (Fig. 2A).
At the end of the induction and mobilization 
phase, the random assignment to high-dose mel-
phalan or MPR was disclosed for the 273 patients 
who were eligible for consolidation therapy. The 
median progression-free survival was significantly 
longer among patients who received high-dose 
melphalan (43.0 months) than among patients 
who received MPR (22.4 months; hazard ratio 
for progression or death, 0.44; 95% confidence 
interval [CI], 0.32 to 0.61; P<0.001) (Fig. 2B). High-
dose melphalan, as compared with MPR, was also 
associated with improvement in the 4-year over-
all survival rate (81.6% vs. 65.3%; hazard ratio for 
death, 0.55; 95% CI, 0.32 to 0.93; P = 0.02) 
(Fig. 2B). The progression-free survival benefit 
associated with high-dose melphalan was con-
sistent across all patient subgroups (Fig. S2 in 
the Supplementary Appendix).
Among the 251 patients who were eligible to 
be included in the second randomized compari-
son (between lenalidomide maintenance therapy 
and no maintenance therapy), median progression-
free survival was significantly longer with lenalid-
omide maintenance therapy than with no mainte-
nance therapy (41.9 months vs. 21.6 months; 
Figure 1 (facing page). Randomization, Treatment,  
and Follow-up of the Enrolled Patients.
MPR denotes melphalan–prednisone–lenalidomide.
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High-dose melphalan plus lenalidomide maintenance
High-dose melphalan plus no maintenance
MPR plus lenalidomide maintenance
MPR plus no maintenance
Hazard ratio for progression
or death with high-dose
melphalan, 0.44 (95% CI,
0.32–0.61); P<0.001
High-dose melphalan MPR
22.4 43.0
Hazard ratio for death with high-dose melphalan,
0.55 (95% CI, 0.32–0.93); P=0.02
Hazard ratio for progression
or death with lenalidomide 
maintenance, 0.47 (95% CI,
0.33–0.65); P<0.001 
Lenalidomide maintenance No maintenance 
21.6 41.9
Hazard ratio for death with lenalidomide maintenance 
0.64 (95% CI, 0.36–1.15); P=0.14
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hazard ratio for progression or death, 0.47; 
95% CI, 0.33 to 0.65; P<0.001) (Fig. 2C). Lenalido-
mide maintenance therapy, as compared with no 
maintenance therapy, had no significant effect on 
the 3-year overall survival rate (88.0% vs. 79.2%; 
hazard ratio for death, 0.64; 95% CI, 0.36 to 
1.15; P = 0.14) (Fig. 2C). The beneficial effect of 
lenalidomide maintenance on progression-free 
survival was homogeneous in all subgroups ex-
cept patients with stage III disease at the time of 
diagnosis (P = 0.04 for the interaction between 
stage and treatment) (Fig. S2 in the Supplemen-
tary Appendix). Results of the subgroup analysis 
of overall survival are shown in Figure S3 in the 
Supplementary Appendix.
No significant differences in progression-free 
survival were detected between the maintenance 
and no-maintenance populations in the compari-
son of high-dose melphalan with MPR (P = 0.99 
for interaction) (Fig. S2 in the Supplementary 
Appendix), or between the high-dose melphalan 
and MPR subgroups in the comparison of le-
nalidomide maintenance therapy with no main-
tenance therapy (P = 0.93 for interaction) (Fig. S2 
in the Supplementary Appendix). Among patients 
with relapsed multiple myeloma, the 3-year over-
all survival rates from the time of relapse were 
similar across the four treatment groups (Fig. S4 
in the Supplementary Appendix). In the MPR 
group, 98 of 156 patients (62.8%) received high-
dose melphalan at relapse, as prespecified in the 
treatment protocol. Details of salvage treatment 
administered at the time of relapse are provided 
in Table S3 in the Supplementary Appendix.
The complete response rate improved from 
15.7% after consolidation therapy to 35.7% after 
maintenance therapy in the high-dose melphalan 
group and from 20.0% after consolidation ther-
apy to 33.8% after maintenance therapy in the 
MPR group (data not shown). Prognostic factors 
such as staging and cytogenetic features did not 
affect the quality of the response.
Safety
During the induction phase, the most frequent 
grade 3 or 4 adverse events were neutropenia (in 
8.5% of the patients), anemia (in 6.3%), infection 
(in 6.0%), and dermatologic events (in 4.8%); one 
death occurred as a result of arrhythmia. In to-
tal, 27 of 399 patients (6.8%) discontinued treat-
ment because of adverse events, and 56 (14.0%) 
discontinued treatment for other reasons (with-
drawal of consent or the investigator’s decision) 
(Table 1).
During consolidation therapy, hematologic 
adverse events occurred more frequently in pa-
tients who received high-dose melphalan than 
in those who received MPR. These events were 
mainly grade 3 or 4 neutropenia (94.3% vs. 51.5%, 
P<0.001) and thrombocytopenia (93.6% vs. 8.3%, 
P<0.001) (Table 1). Other grade 3 or 4 adverse 
events that were more common in patients who 
received high-dose melphalan were gastrointes-
tinal events (18.4% vs. 0%, P<0.001), infections 
(16.3% vs. 0.8%, P<0.001), and systemic events 
(12.8% vs. 1.5%, P<0.001).
During the maintenance phase, the most fre-
quent grade 3 or 4 adverse events were neutrope-
nia (in 23.3% of patients who received lenalido-
mide maintenance therapy vs. 0% of patients who 
received no maintenance therapy, P<0.001), in-
fections (in 6.0% vs. 1.7%, P = 0.09), and derma-
tologic events (in 4.3% vs. 0%, P = 0.03) (Table 1). 
Reduced doses of lenalidomide were required in 
14.7% of patients (Table S5 in the Supplemen-
tary Appendix); 5.2% of patients discontinued 
lenalidomide because of toxicity (Table S6 in the 
Supplementary Appendix).
Eleven patients (2.8%) had a second primary 
cancer: lung cancer in one patient during induc-
tion; prostate cancer in two patients and breast 
cancer in three patients during lenalidomide main-
tenance therapy; and one case each of myelodys-
plasia, lung cancer, bladder cancer, colon cancer, 
and biliary tract cancer after consolidation ther-
Figure 2 (facing page). Kaplan–Meier Estimates  
of Progression-free Survival and Overall Survival.
Panel A shows progression-free survival and 5-year 
overall survival from the time of diagnosis among pa-
tients who received high-dose melphalan followed by 
lenalidomide maintenance therapy, those who received 
high-dose melphalan with no subsequent maintenance 
therapy, those who received MPR followed by lenalido-
mide maintenance therapy, and those who received 
MPR with no subsequent maintenance therapy. Panel 
B shows progression-free survival and 4-year overall 
survival from the start of consolidation therapy. Panel 
C shows progression-free survival and 3-year overall 
survival from the start of maintenance or no mainte-
nance. The median progression-free survival is shown 
within the graph in the left side of each panel. CI de-
notes confidence interval.
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apy in patients who were randomly assigned to no 
maintenance therapy.
Discussion
In this randomized study involving patients with 
newly diagnosed multiple myeloma, the stan-
dard high-dose melphalan consolidation therapy 
followed by stem-cell transplantation, as compared 
with MPR, was associated with a significant re-
duction in the risk of progression or death (haz-
ard ratio, 0.44) and prolonged overall survival 
(hazard ratio for death, 0.55). Maintenance treat-
ment with lenalidomide, as compared with no 
maintenance, was associated with a significantly 
reduced risk of disease progression or death (haz-
ard ratio, 0.47). The best treatment strategy (in-
duction followed by high-dose melphalan and 
lenalidomide maintenance) was associated with 
a 5-year rate of progression-free survival from the 
time of diagnosis of approximately 48% and an 
overall survival rate of 78% among all patients. 
These results confirm a net clinical benefit of 
high-dose melphalan administration as consoli-
dation treatment and provide support for the ben-
efit of lenalidomide as continuous treatment.
Despite a similar complete response rate with 
the two consolidation regimens, high-dose mel-
phalan improved progression-free survival. Un-
fortunately, the response was assessed with the 
use of standard laboratory tests, and minimal 
residual disease was not monitored with immu-
nophenotypic or molecular techniques, which 
might have revealed more subtle differences in 
the response, as reported in similar studies.25 
The clinical benefit was seen consistently across 
Event Induction Phase Consolidation Phase Maintenance Phase
Lenalidomide– 
Dexamethasone 
(N = 399)
High-Dose 
Melphalan 
(N = 141)
MPR 
(N = 132)
Lenalidomide 
Maintenance 
(N = 116)
No 
Maintenance 
(N = 115)
number of patients (percent)
Hematologic adverse events
Neutropenia 34 (8.5) 133 (94.3) 68 (51.5) 27 (23.3) 0
Thrombocytopenia 12 (3.0) 132 (93.6) 11 (8.3) 5 (4.3) 0
Anemia 25 (6.3) 32 (22.7) 2 (1.5) 2 (1.7) 0
Nonhematologic adverse events
Gastrointestinal event† 7 (1.8) 26 (18.4) 0 — —
Infection‡ 24 (6.0) 23 (16.3) 1 (0.8) 7 (6.0) 2 (1.7)
Systemic event§ 10 (2.5) 18 (12.8) 2 (1.5) — —
Dermatologic event¶ 19 (4.8) — — 5 (4.3) 0
Vascular event‖ 8 (2.0) 1 (0.7) 2 (1.5) 2 (1.7) 0 
Second primary cancer — no. (%)** 1 (0.3) 0 0 5 (4.3) 5 (4.3)
Discontinuation of therapy due to adverse event 16 (4.0) 1 (0.7) 4 (3.0) 6 (5.2) 0 
Discontinuation of therapy for other reasons
Withdrawal of consent 13 (3.3) 8 (5.7) 1 (0.8) 6 (5.2) 0 
Investigator’s decision 21 (5.3) 4 (2.8) 0 3 (2.6) 0 
*  In categories for which no data are shown, the incidence was less than 2%.
†  Gastrointestinal events included mucositis, nausea, vomiting, diarrhea, and constipation.
‡  Infections included pneumonia, bronchitis, sepsis, herpes zoster, gastrointestinal tract infection, influenza, cytomegalovirus infection,  
febrile neutropenia, and Clostridium difficile infection.
§  Systemic events included fatigue and fever of unknown origin.
¶  Dermatologic events included rash.
‖  Vascular events included deep-vein thrombosis, phlebitis, and pulmonary thromboembolic events.
**  Second primary cancers were lung, prostate, breast, bladder, colon, and biliary tract cancers and myelodysplasia.
Table 1. Grade 3 and 4 Adverse Events Occurring in at Least 2% of the Safety Population.*
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the various patient subgroups. High-dose melpha-
lan, as compared with MPR, was also associated 
with significant improvement in overall survival.
Hematologic and nonhematologic adverse 
events were more frequent with high-dose mel-
phalan than with MPR. However, toxic effects 
were manageable and did not affect the rate of 
early death or treatment discontinuation or pa-
tients’ ability to proceed to the maintenance or 
no-maintenance phase. Although stem cells were 
obtained from all patients at diagnosis, stem-cell 
transplantation was performed in only 62.8% of 
patients in the MPR group at the time of relapse, 
in most cases because of a rapid worsening of 
their clinical condition or the patient’s decision 
to decline transplantation. Thus, stem-cell trans-
plantation is not always feasible at the time of 
relapse, and the option of delayed transplanta-
tion should be suggested with caution.
The clinical benefit associated with lenalido-
mide maintenance was independent of the con-
solidation regimen. Response rates improved dur-
ing maintenance therapy in both the high-dose 
melphalan and MPR groups. As compared with 
no maintenance, low-dose lenalidomide mainte-
nance delayed relapse by approximately 2 years. 
Previous studies have shown that lenalidomide 
maintenance prolonged the duration of remis-
sion by 17, 18, and 19 months,16-18 but an overall 
survival benefit was observed in only one of the 
three studies.17 In our study, lenalidomide main-
tenance, as compared with no maintenance, was 
associated with significantly prolonged progres-
sion-free survival; no significant improvement in 
overall survival was noted. A longer follow-up 
study is needed to better evaluate the benefit of 
a delayed clinical relapse and the risk of chemo-
resistance after maintenance therapy. The benefit 
of maintenance therapy was seen in most sub-
groups, but a prespecified subgroup comparison 
showed no benefit in patients with stage III dis-
ease (hazard ratio, 1.06; P = 0.04 for interaction).
Maintenance treatment with lenalidomide, as 
compared with no maintenance, was associated 
with more frequent grade 3 or 4 adverse events 
— mainly neutropenia and infections. Although 
maintenance therapy is effective in prolonging 
the duration of remission, it should be adminis-
tered carefully to avoid toxic effects that may 
reduce the patient’s quality of life. The rate of 
second primary cancers was low, and no between-
group differences were reported.
This study had some limitations. First, only 
68% of the enrolled patients were eligible to 
undergo the first randomization; the main rea-
sons for discontinuation during the induction 
phase were disease progression and the patient’s 
decision to choose an alternative therapy be-
cause of a suboptimal response after induction. 
Second, we investigated only lenalidomide and 
did not include bortezomib in the treatment plan. 
Bortezomib-based induction and consolidation 
regimens in combination with alkylating or im-
munomodulatory agents have been associated 
with unprecedented rates of high-quality response 
and a positive effect on outcomes in patients, 
regardless of whether they are eligible for stem-
cell transplantation.8,12 Third, placebo was not 
administered in the group of patients who did 
not receive maintenance therapy, and a blind as-
sessment of progression was not made. Finally, 
quality-of-life assessments were not performed.
Ongoing large collaborative studies (the Eu-
ropean Myeloma Network 02 trial and the Inter-
groupe Francophone du Myélome/Dana–Farber 
Cancer Institute 2009 trial; ClinicalTrials.gov 
numbers NCT01208766, NCT01191060, and 
NCT01208662) are evaluating effective drug 
combinations that include a proteasome inhibi-
tor versus autologous stem-cell transplantation, 
the benefit of early versus late transplantation, 
and the effects of varying the duration of main-
tenance therapy. Results of these trials may shed 
further light on this important clinical area.
In conclusion, we found that consolidation 
therapy with high-dose melphalan, as compared 
with MPR, improved progression-free and over-
all survival, although at a cost of increased toxic-
ity. Our findings confirm that high-dose mel-
phalan remains the more effective therapeutic 
option in patients with newly diagnosed multi-
ple myeloma. We also found that maintenance 
therapy with lenalidomide, as compared with no 
maintenance therapy, significantly reduced the 
risk of disease progression.
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